Physician profile
Ling Lo
NPI 1093734568
$5,736.80
in general payments reported to CMS, 2019-2025
38 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.16 · 2021: $2,873 · 2022: $367 · 2023: $445 · 2024: $1,681 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,400.74 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $616.42 | 2021-2024 | Padcev, Xtandi, Xospata |
| Glaxosmithkline, LLC. | $501.21 | 2021-2025 | Ojjaara, Zejula |
| E.R. Squibb & Sons, L.L.C. | $416.68 | 2021-2025 | Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $290.48 | 2021-2024 | Keytruda, Lynparza |
| Pfizer INC. | $282.29 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.23 | 2022-2023 | Fruzaqla |
| Lilly USA, LLC | $217.48 | 2021 | |
| Beigene USA, INC. | $192.73 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $186.69 | 2021-2024 | Calquence |
| Incyte Corporation | $132.61 | 2021 | |
| Kite Pharma, INC. | $130.32 | 2021 | |
| Gilead Sciences, INC. | $121.85 | 2022 | |
| Aveo Pharmaceuticals, INC. | $106.01 | 2021 | |
| Emd Serono, INC. | $103.15 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $90.86 | 2025 | Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $90.62 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $86.33 | 2021 | |
| Exelixis INC. | $64.97 | 2021 | |
| Seagen INC. | $46.18 | 2021 | |
| Morphosys, US INC. | $45.78 | 2021 | |
| Abbvie INC. | $39.37 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $38.62 | 2021 | |
| Janssen Scientific Affairs, LLC | $32.58 | 2024 | Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.58 | 2021 | |
| Karyopharm Therapeutics INC. | $27.96 | 2021 | |
| Amag Pharmaceuticals, INC. | $27.34 | 2021 | |
| Myovant Sciences INC. | $22.65 | 2021 | |
| Daiichi Sankyo INC. | $21.21 | 2021 | |
| Dova Pharmaceuticals | $20.77 | 2021 | |
| Blueprint Medicines Corporation | $19.18 | 2021 | |
| Foundation Medicine, INC. | $17.27 | 2023 | |
| Boston Scientific Corporation | $16.16 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.56 | 2021 | |
| Coherus Oncology, INC. | $13.53 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $12.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.